Curevac N V (CVAC) Return on Equity ROE from the second quarter 2025 to second quarter 2024 and annually, average high and low, overall ranking from Jun 30 2025 to 0 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Curevac N v   (NASDAQ: CVAC)

Curevac N V 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Curevac N V in the second quarter 2025?
Curevac N v achieved a return on average equity (ROE) of 28.18 % in its second quarter 2025, this is above CVAC's average return on equity of -24.34%.
Curevac N V shareholder's equity over the 12 months ending in its second quarter 2025 are valued at $737 million

While the company's net income was fading, Curevac N V was able to improve its ROE compared to the first quarter 2025.

Within the Major Pharmaceutical Preparations industry 25 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the first quarter 2025 from 537 to 580.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Jun 30 2025)
II. Quarter		 (Mar 31 2025)
I. Quarter		 (Dec 31 2024)
IV. Quarter		 0
III. Quarter		 0
II. Quarter
Y / Y Equity Change -11.54 % -10.51 % 34.76 % 34.76 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions 208 197 175 123 -301
Return On Equity (TTM) 28.18 % 25.96 % 22.49 % 16.89 % -44.3 %
CVAC's Total Ranking # 580 # 537 # # #
Equity (TTM) in Millions 690 698 780 780 780
Seq. Equity Change -1.15 % -10.51 % 0 % 0 % 0 %
Seq. Net Income Change - - - - -

Back to CVAC Management Effectiveness >> CVAC's 5 Years Annual ROE >> Compare CVAC ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 26
Sector # 65
Overall # 580

Return On Equity Statistics
High Average Low
23.28 %
-24.34 %
-50.33 %
(Dec 31 2024)   (Dec 31 2023)





CVAC Annual Return On Equity (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2020)
2020
Total Equity in Millions 780 579 570 797 0
Y / Y Equity Change 34.76 % 1.49 % -28.4 % - -
Net Income in Millions 182 -291 -262 -145 0
Y / Y Net Income Change - - - - -
Return On Equity 23.28 % -50.33 % -45.99 % -18.15 % -

Back to CVAC Management Effectiveness >> CVAC's 5 Years Annual ROE >> Compare CVAC ROE to its Competitors




Annual Roe Comment
In 2024 ROE improved to 23.28 % compared to the previous year, due to net income growth.


More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
CVAC's' Return on Equity at Yahoo Finance
CVAC's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for CVAC's Competitors
Subscribers only: Roe for Curevac N V 's Suppliers
Subscribers only: Return On Equity for CVAC's Customers




Companies with similar Return On Equity at Jun 30 2025, within Healthcare Sector ROE
Biomx Inc  70.26 %
Medpace Holdings Inc   67.66 %
Dariohealth Corp   65.89 %
Medinotec Inc   65.57 %
Idexx Laboratories Inc  64.42 %
Exelixis Inc   63.47 %
Adma Biologics Inc   61.78 %
Nrc Health  61.35 %
Arcutis Biotherapeutics Inc   59.20 %
Illumina Inc   55.11 %
Puma Biotechnology Inc   53.09 %
Zoetis Inc   51.76 %
Concentra Group Holdings Parent Inc   50.78 %
Synlogic Inc   46.41 %
Entera Bio Ltd   46.01 %
Longduoduo Co Ltd  44.99 %
Agios Pharmaceuticals Inc   43.31 %
Tenet Healthcare Corp  42.43 %
Agilent Technologies inc   42.04 %
Edwards Lifesciences Corporation  40.93 %
Siga Technologies Inc  40.55 %
Hims and Hers Health Inc   38.17 %
Waters Corporation  34.91 %
Merck and Co Inc   34.86 %
Gilead Sciences Inc   33.08 %
Sbc Medical Group Holdings Incorporated  32.69 %
Eledon Pharmaceuticals Inc   32.28 %
Lifevantage Corp  32.06 %
Nutriband Inc   30.91 %
Acadia Pharmaceuticals Inc   30.67 %

Date modified: 2026-09-18T16:09:18+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.